Use of topical human amniotic fluid in the treatment of acute ocular alkali injuries in mice.
OBJECTIVE
To evaluate the efficacy of topical human amniotic fluid (HAF) in the treatment of ocular acute alkali burns in mice.


METHODS
Experimental study.


METHODS
A chemical burn with 2 microl of sodium hydroxide 0.15 mol/l was created in one eye of 30 mice. The animals were divided into gender- and age-matched groups according to the topical treatment that was administered: group 1 was treated with preterm HAF (n = 10 mice); group 2 was treated with term HAF (n = 10 mice), and group 3 was treated with saline solution (n = 10 mice). Treatment consisted of one drop that was applied to the burned eye five times per day (week one), and three times per day (week two). The epithelial defect was photographed and measured on days two and four. Ocular burn damage was assessed at days two, seven, and 14 after a pre-established classification. On day 14, both eyes of each mouse were enucleated and assessed histopathologically.


RESULTS
Median epithelial defect (interquartile range [IQR], 25th, 75th percentile) at day four was 9.93% (IQR, 8.57, 11.27) for group 1, 7.30% (IQR, 5.96, 8.97) for group 2, and 18.92% (IQR, 11.71, 27.64) for group 3 (P < .0076). The overall change (difference in slope) in ocular burn score between days 2 and 14 was -0.127 (P = .009) in group 1 vs 3, -0.134 (P = .012) in group 2 vs 3, and 0.007 (P = .88) in group 1 vs 2. On histologic examination saline solution-treated corneas had more inflammatory cells and blood vessels than HAF-treated corneas.


CONCLUSIONS
Topical preterm/term HAF was an effective topical therapy for limiting the damage after acute alkali burns of the eye in this animal model.
Herretes
Samantha
S
The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Suwan-Apichon
Olan
O
Pirouzmanesh
Ashkan
A
Reyes
Johann M G
JM
Broman
Aimee T
AT
Cano
Marisol
M
Gehlbach
Peter L
PL
Gurewitsch
Edith D
ED
Duh
Elia J
EJ
Behrens
Ashley
A
D000208:Acute Disease; D000287:Administration, Topical; D000653:Amniotic Fluid / Q000502:physiology*; D000818:Animals; D002057:Burns, Chemical / Q000473:pathology / Q000628:therapy*; D003316:Corneal Diseases / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D019573:Epithelium, Corneal / Q000187:drug effects / Q000473:pathology; D005126:Eye Burns / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D012972:Sodium Hydroxide / Q000633:toxicity
D012972:Sodium Hydroxide